Insights

The study of longevity, and the factors that contribute to it, has become a topic of increasing interest in recent years. Advances in genetic research, as well as a deeper understanding of the impact of lifestyle and environmental factors, have led to new insights into how we can potentially extend our healthy lifespan. This article ...

Editor’s Note: As the industry of longevity continues to expand and evolve in 2023 (see the 2022 milestones here), Spannr is dedicated to providing our readers with a comprehensive understanding of the field and all the exciting possibilities it holds. To that end, we invite you to consider the following as an introduction to the world ...

The Spannr Longevity Stock Index was introduced in 2022 as the first index of its kind to provide real-time tracking of the entire public longevity market. The index was launched in May 2022 and the previous quarter, Q4, marks only the second full quarter of the index being live and operational. In this report, we ...

In the latest addition to our interview series, we sit down with Cole Kirschner, the visionary CEO and co-founder of AgeRate. In this interview, Cole shares the origin story of his direct-to-consumer longevity startup, which uses blood tests to reveal to consumers how well they are aging and give them the tools and knowledge they ...

The past year has been pretty epic for us folks interested in defying aging. Aside from Spannr officially launching (we know, big deal), there’s been many developments in the space that we can all hang our hats on. But before we even go there, let’s first take a step back… The Bigger Picture Longevity… Biotech… ...

Longevity clinics are becoming increasingly popular as people strive to stay healthy and vital for as long as possible. These clinics focus on the early detection and treatment of diseases that are age-dependent, and the prolongation of the active phase of a person’s life, in which mental, physical, and social activities are preserved. There are ...

November’s Funding Roundup: $602.5M Raised Across 14 Funding Rounds Jnana Therapeutics, a biotech company leveraging its chemoproteomics platform to discover medicines for challenging-to-drug targets, raises $107 Million Series C from Bain Capital Life Sciences with participation from RA Capital Management, Polaris Partners, Versant Ventures, Avalon Ventures & Pfizer Ventures Nymbl Science, a digital balance trainer, ...

We all want to live a long and healthy life, but as we age, various forms of biological damage result in increased susceptibility for disease. As a result, longevity supplements are becoming increasingly popular as people look for ways to improve their health and extend their life. This article examines the science underpinning 7 popular ...

The Longevity Biotech Fellowship (LBF) – a non-profit community aiming to bring people together to help progress the revolutionary field of longevity – is back, opening its doors to a new cohort of entrepreneurs, students, and investors. The upcoming program that’s set to launch in January 2023 represents LBF’s third cohort since its inception. Applications ...

NMN supplements, a market estimated to be worth $280.2 million this year, just got a no-go from the FDA, curbing many “anti-aging” supplement providers and longevity enthusiasts from interacting with one of the most popular longevity supplements on the market. While the news has stirred up a bit of drama and finger-pointing, which we’ll eventually ...